Photodynamic therapy proves worth in UK assessment, but more research needed
This article was originally published in Clinica
Photodynamic therapy (PDT) “shows potential” for the treatment of pre-cancerous skin conditions, Barrett's oesophagus and certain cancers, but its value in comparison with other technologies remains unclear. So concluded a study just published by a team at the UK’s Centre for Reviews and Dissemination, University of York, following a health technology assessment (HTA) commissioned for the NHS. The cancers it considered were of the: biliary tract, brain, head/neck, lung, oesophagus and skin. “PDT showed potential promise...across the conditions and sites investigated. However, its place in relation to other available treatments was unclear and there is a need for further, high quality research in this area,” the team concluded.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.